Long-term care & seniors

Booster doses stimulate strong antibody responses, including in older adults

While two doses of COVID-19 vaccine can prevent serious illness in most cases, vaccine-induced immune responses decline naturally over time, which leads to an increased risk of breakthrough infections. A pre-print, not-yet peer-reviewed, from CITF-funded researchers Dr. Mark Brockman of Simon Fraser University, Dr. Zabrina Brumme of Simon Fraser University and the BC Centre [...]

2022-01-17T16:03:44-05:00January 17, 2022|Long-term care & seniors|

Boosting immunity in the elderly

In a pre-print, not yet peer reviewed, study led by CITF-funded researchers Drs. Andrew Costa and Dawn Bowdish at McMaster University, people in retirement or nursing homes had repeat blood samples taken to measure immunity after the second and third doses of SARS-COV-2 mRNA vaccines. Researchers found that the third vaccine dose brought about [...]

2022-01-10T10:35:12-05:00January 10, 2022|Long-term care & seniors|

One in five vaccinated long-term care residents at risk of COVID-19 because of low antibody levels, supporting need for booster shots

Findings from a CITF-funded study led by Drs. Andrew Costa and Dawn Bowdish at McMaster University helped inform the federal government’s decision to recommend a third dose of COVID-19 vaccine for long-term care residents. More than 97% of residents produced an initial antibody response to vaccination that is likely to provide protection against the [...]

2021-11-16T16:20:50-05:00November 12, 2021|Long-term care & seniors|

mRNA vaccines administered with an extended interval between doses elicit strong SARS-CoV-2 antibody responses after two doses

Findings from a real-world vaccination study composed of seniors residing in long-term care facilities were recently released in preprint, therefore not yet peer-reviewed, on behalf of investigators from the CITF-funded study UNCoVER (including Dr. Donald Vinh, Research Institute of the McGill University Health Centre (RI-MUHC) and Dr. Marc-André Langlois, University of Ottawa) and the [...]

2021-10-05T10:23:44-04:00October 5, 2021|Long-term care & seniors|

Not all immune responses are created equal: antibody responses 3-5 months post-vaccination with Moderna or Pfizer in long-term care residents

In a recent CITF-funded study, not yet peer-reviewed, researchers from McMaster University Dr. Andrew Costa and Dr. Dawn Bowdish, in collaboration with the COVID in Long Term Care Study Group, examined immunity responses to COVID-19 vaccines in nursing home residents after two doses of Moderna or Pfizer-BioNTech vaccines. They found that most seniors elicited [...]

2021-08-24T12:56:28-04:00August 24, 2021|Long-term care & seniors|

Monitoring COVID-19 immunity in long-term care via sewage

Published recently in BMJ Open, researchers Drs. Xiao-Li Pang, Bonita Lee and Christopher Sikora outline their CITF-funded study protocol for monitoring COVID-19 immunity using two very different channels: sewage and blood. The first arm of their study makes use of site-specific sewage sampling strategies that will enable early detection of SARS-CoV-2 outbreaks in long-term [...]

2021-08-24T12:50:11-04:00August 24, 2021|Long-term care & seniors|

Study results show subtle differences in antibody response between Pfizer and Moderna vaccines for residents of long-term care

This CITF-funded research, which is in pre-print, was led by Lunenfeld-Tanenbaum Research Institute (LTRI) senior scientists Dr. Anne-Claude Gingras and Dr. Allison McGeer and reveals that long-term care (LTC) residents in Ontario who received the Pfizer vaccine had lower antibody responses to Alpha, Beta and Gamma than those vaccinated with the Moderna vaccine. The Delta variant was not assessed.

2021-08-17T11:11:28-04:00August 17, 2021|Long-term care & seniors, Media Releases|

Antibody production following immunization by mRNA vaccines in Ontario long-term care residents and staff

Long-term care residents and staff immunized with the Moderna vaccine elicited stronger total and neutralizing antibody responses compared to those vaccinated with Pfizer-BioNTech, according to new research. The preprint findings, yet to be peer-reviewed, also illustrate differences between the ability of the two mRNA vaccines to neutralize variants of concern (VOCs). Notably, about 38% [...]

2021-08-17T11:41:48-04:00August 17, 2021|Long-term care & seniors|

Not all retirement homes have the same COVID-19 risk for residents

Dr. Andrew Costa, from McMaster University, and colleagues, have studied the risk factors for SARS-CoV-2 outbreaks at retirement homes or assisted living facilities in Ontario. In a publication in the Canadian Medical Association Journal, now also available in French, they find that the risk of a COVID-19 outbreak is higher in homes with larger resident [...]

2021-07-05T15:16:07-04:00May 18, 2021|Long-term care & seniors|

Weaker antibody response to first COVID-19 vaccine dose found in long-term care residents

New data stemming from a study in British Columbia evaluating the strength and magnitude of antibody responses following one dose of the Pfizer-BioNTech vaccine indicate that older adults generate a much weaker antibody response to one vaccine dose compared to younger adults. These findings (in preprint and therefore not yet peer reviewed) hail from [...]

2021-03-25T15:12:54-04:00March 25, 2021|Long-term care & seniors|
Go to Top